Mobile Technology for Hemolysis Detection
Prenatal conditions are the fourth leading cause of death in developing nations and still pose significant health risks in countries with high income. More than 200,000 pregnant women and newborns are affected each year and according to the World Health Organization eclampsia and its complications are the reason for 25% of maternal deaths worldwide in addition to fetal and neonatal death. Preeclampsia can rapidly escalate to a dangerous complication known as HELLP syndrome. One of the ways to diagnose HELLP syndrome is to detect the onset of in-vivo hemolysis - a condition which occurs when red blood cells (RBCs) are lysed releasing hemoglobin into blood plasma. Hemolysis cannot be detected in whole blood because of the presence of cells; therefore, centrifugation and plasma separation are required to assess level of hemoglobin in plasma. There is a need for a technology that can work with just a drop of whole blood and promptly and reliably measure hemoglobin concentration in plasma. The application uses a camera to determine the level of hemoglobin in plasma based on color. Add on components may be attached to the phone to hold the sample
in place and block unneeded light.
US 9,547,899 issued 2017-01-17 [MORE INFO
Type of Offer:
« More Biology Patents« More Technology Patents